Krishna Institute of Medical Sciences Limited has informed the Exchange regarding Board meeting held on August 06, 2025.
KIMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Krishna Institute of Medical Sciences Limited (KIMS) announced its Q1 FY26 results after a board meeting on August 6, 2025. Consolidated revenue from operations grew 26.6% YoY to ₹8,716 million from ₹6,884 million in Q1 FY25. However, consolidated profit after tax declined about 10.7% to ₹850 million from ₹952 million, and EPS fell to ₹1.96 from ₹2.16. Standalone revenue grew about 14% YoY to ₹3,734 million while standalone PAT dipped to ₹588 million from ₹607 million. Total expenses grew faster than revenue (around 35% YoY at consolidated level), driven by higher employee costs, finance costs, and other expenses, which squeezed margins. The statutory auditor, S.R. Batliboi & Associates LLP, issued an unmodified (clean) review opinion on both sets of results. Four subsidiaries reported an aggregate net loss of ₹138 million, partially weighing on consolidated earnings.
Strong top-line growth signals healthy business expansion across KIMS hospital network, but the sharp rise in operating and finance costs has compressed profitability, which may temper near-term investor enthusiasm. Watch for margin trends in coming quarters to see if the cost pressure is temporary (expansion-related) or structural.